Tranzyme Pharma Announces Successful Thorough QT/QTc Study Of Ghrelin Agonist TZP-101
Jun 30th 2008Drug InformationGastroIntestinal / Gastroentorology
Tranzyme Pharma announces the successful results from a “Thorough QT/QTc” study of the company’s lead product TZP-101, an intravenous gastrointestinal prokinetic agent currently in two Phase IIb trials for the treatment of postoperative ileus (POI) and severe gastroparesis.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
